SLU-PP-332 is primarily used in scientific research as a selective agonist for the GPR55 receptor, which is involved in various physiological processes including pain modulation, inflammation, and bone metabolism. It serves as a valuable tool compound for studying the endocannabinoid system and related signaling pathways. Researchers utilize SLU-PP-332 to investigate receptor activation mechanisms and downstream effects in cellular and animal models. Its application supports the development of potential therapeutics targeting metabolic disorders, neuropathic pain, and osteoporosis. Due to its specificity, it helps differentiate GPR55-mediated effects from those of classical cannabinoid receptors.